Related Experiment Video

Updated: May 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from

Jean-Claude Tardif1, Eileen O'Meara, Michel Komajda

  • 1Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec, Canada H1T 1C8. jean-claude.tardif@icm-mhi.org

European Heart Journal
|August 31, 2011
PubMed

Insights

Ivabradine effectively reduced left ventricular remodelling in heart failure patients. This treatment improved key cardiac function metrics and was associated with better clinical outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Imaging

Background:

  • Heart failure (HF) with systolic dysfunction is characterized by left ventricular (LV) remodelling.
  • Effective treatments targeting LV remodelling are crucial for improving outcomes in HF patients.

Purpose of the Study:

  • To evaluate the impact of ivabradine on left ventricular remodelling in patients with chronic heart failure.
  • To assess the effects of ivabradine on LV end-diastolic volume index and LV ejection fraction.

Main Methods:

  • The SHIFT echocardiographic substudy enrolled patients with chronic HF, LVEF ≤35%, sinus rhythm, and resting heart rate ≥70 bpm.
  • Patients received either ivabradine or placebo, in addition to standard HF therapy.
  • Echocardiographic parameters were analyzed at baseline and after 8 months in 411 patients.

Main Results:

  • Ivabradine significantly reduced LV end-systolic volume index (LVESVI) compared to placebo (P<0.001).
  • Improvements were observed in LV end-diastolic volume index (P=0.002) and LV ejection fraction (P<0.001) with ivabradine.
  • Reduced LVESVI was associated with lower rates of cardiovascular mortality or HF hospitalizations.

Conclusions:

  • Ivabradine demonstrates significant efficacy in reversing cardiac remodelling in HF patients.
  • The findings support ivabradine as a therapeutic option for managing HF with systolic dysfunction.
  • Targeting LV remodelling with ivabradine may improve clinical outcomes in heart failure.
Abstract

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...